Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Journal of Antimicro...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Journal of Antimicrobial Chemotherapy
Article . 2020 . Peer-reviewed
License: OUP Standard Publication Reuse
Data sources: Crossref
Journal of Antimicrobial Chemotherapy
Article . 2021
Data sources: Europe PubMed Central
UQ eSpace
Article . 2020
Data sources: UQ eSpace
https://dx.doi.org/10.1093/jac...
Article
Data sources: Microsoft Academic Graph
The University of Queensland: UQ eSpace
Article . 2020
Data sources: Bielefeld Academic Search Engine (BASE)
 View all 3 versions
Claim

Pandrug-resistant Acinetobacter baumannii treatment: still a debatable topic with no definite solutions

descriptionPublicationkeyboard_double_arrow_right Article 29 Jun 2020 Australia English Publisher:Oxford University Press (OUP)Journal:Journal of Antimicrobial Chemotherapy, volume 75, pages 3,081-3,081 (issn: 0305-7453, eissn: 1460-2091, Copyright policy )
Authors: Georgios Papathanakos; Ioannis Andrianopoulos; Athanasios Papathanasiou; Despoina Koulenti; Konstantina Gartzonika; Vasilios Koulouras;

doi: 10.1093/jac/dkaa264

pmid: 32596722

Pandrug-resistant Acinetobacter baumannii treatment: still a debatable topic with no definite solutions

Keywords

Pharmacology, Acinetobacter baumannii, 2725 Infectious Diseases, Prognosis, 2726 Microbiology (medical), 3004 Pharmacology, Infectious Diseases, Drug Resistance, Multiple, Bacterial, 2736 Pharmacology (medical), Humans, Pharmacology (medical), Acinetobacter Infections

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 10
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Top 10%
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Top 10%
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
10
Top 10%
Average
Top 10%
hybrid